Eleni Efstathiou
Houston Methodist · 406 works · 22,354 citations · h-index 63
Top works
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
- Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
- Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response
- Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
- Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology
- Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
- Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5
- Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer